PCOS Clinical Trial
Official title:
Comparing the Effect of Metformin vs. Pep2dia as an Adjunct to Letrozole on Ovulation Induction and Pregnancy Outcomes in Overweight Women With PCOS; A Randomized Controlled Open-Label Pilot Study
The goal of this clinical trial is to compare the effects of Metformin versus Pep2dia as adjunct treatments to Letrozole on ovulation induction and pregnancy outcomes in overweight women with polycystic ovary syndrome (PCOS). The main questions it aims to answer are: Does Metformin improve ovulation rates more effectively than Pep2dia when used alongside Letrozole? Does Pep2dia enhance pregnancy outcomes compared to Metformin in this patient population? Participants will: Receive either Metformin or Pep2dia in addition to Letrozole. Undergo regular monitoring for ovulation and pregnancy outcomes. Researchers will compare the Metformin group to the Pep2dia group to see if there is a significant difference in ovulation and pregnancy rates between the two treatments.
Status | Not yet recruiting |
Enrollment | 100 |
Est. completion date | July 1, 2025 |
Est. primary completion date | June 1, 2025 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 35 Years |
Eligibility | Inclusion Criteria: 1. Anovulatory infertile women with PCOS for more than one year associated with overweight and seeking pregnancy. 2. Married women of reproductive age who lived with a husband and were sexually active. 3. Women with resistant to Letrozole. 4. Normal value of prolactin hormone. 5. Age group; 18-35 years 6. BMI ranging from 25 to 29 kg /m². 7. Standard parameters of the husband's semen 8. Diagnostic criteria for Rotterdam diagnosis of polycystic ovary syndrome: Two of the following three criteria are required: - Oligoovulation or Anovulation - Hyperandrogenism: Clinical (hirsutism or less commonly male pattern alopecia) or Biochemical (raised free androgen index (FAI) or free testosterone). - Polycystic ovaries on ultrasound (Christ et al., 2023). Exclusion Criteria: 1. Hypersensitivity to letrozole, metformin or pep2dia. 2. Obese women with BMI =29 kg/m² or women with BMI <25 kg/m². 3. FSH above 11 mg. 4. Any other cause of infertility other than anovulation due to overweight as uterine factor, tubal factor, male factor, ovarian pathology or endometriosis. 5. Any medical disorder that may affect pregnancy or systemic disease (cardiovascular, renal, hepatic, CNS diseases and hypo or hyperthyroidism) 6. Missed patient 7. Discontinuation of drug due to its side effects |
Country | Name | City | State |
---|---|---|---|
Egypt | Al-Hussein University Hospital | Cairo |
Lead Sponsor | Collaborator |
---|---|
Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pregnancy rate: | detected by positive pregnancy test in serum (Chemical pregnancy) or presence of intrauterine gestational sac (Clinical pregnancy) | 6 months | |
Secondary | Ovulation rate: | detected by folliculometry and midluteal progesterone in serum (higher than 3 ng/mL) | 6 months | |
Secondary | Menstrual cycle regulation | Detection of regulation of the menstrual cycle that is not regular in patients with PCOS assessed as cycle length 21-35 days. | 6 months | |
Secondary | Side effects of both agents | Monitoring and recording of any adverse effects experienced by participants during the study period | Throughout the study time (up to 1 year). | |
Secondary | Ongoing pregnancy rate after the first trimester | Assessment of the proportion of pregnancies that progress beyond the first trimester | first 13 weeks in pregnancy. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06101147 -
Effect of Vitamin D Supplementation on Testosterone Level in Women With Polycystic Ovary Syndrome
|
Phase 2 | |
Completed |
NCT02037672 -
PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome
|
Phase 4 | |
Completed |
NCT01833949 -
Unilateral Laparoscopic Diathermy Adjusted to Ovarian Volume
|
N/A | |
Completed |
NCT03608813 -
Myo-inositol, D-chiro-inositol and Glucomannan in PCOS
|
||
Not yet recruiting |
NCT05298657 -
The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment
|
||
Completed |
NCT05951309 -
Myoinositol Treatment and Asprosin Levels in PCOS
|
N/A | |
Enrolling by invitation |
NCT04485403 -
The Effect of Ibuprofen on Women With PCOS.
|
Phase 2 | |
Not yet recruiting |
NCT03978013 -
Pomegranate Juice Effect on Oxidative Stress in Infertile Women During IVF Treatment
|
N/A | |
Recruiting |
NCT03767569 -
Myo-inositol as Pretreatment in Hyperandrogenic PCOS Patients
|
Phase 3 | |
Completed |
NCT05843955 -
Non-alcoholic Fatty Liver Disease in Women With Polycystic Ovary Syndrome
|
||
Recruiting |
NCT05971849 -
Dampening the Reproductive Axis With Continuous Kisspeptin
|
Phase 1 | |
Recruiting |
NCT04597099 -
Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion
|
Early Phase 1 | |
Active, not recruiting |
NCT05206448 -
Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation
|
Phase 4 | |
Recruiting |
NCT02358421 -
Prediction of High Ovarian Response After Assisted Reproductive Techniques
|
N/A | |
Completed |
NCT04113889 -
Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress in Patients With Poly Cystic Ovary Syndrome
|
Phase 2 | |
Completed |
NCT04562883 -
Single vs. Group CAPA-IVM Culture of Cumulus-oocyte Complexes
|
N/A | |
Recruiting |
NCT03264638 -
A Clinical and Biological Research of Combined Chinese and Western Medicine in the Treatment of PCOS
|
Phase 2 | |
Completed |
NCT00594217 -
Determining How Quickly Progesterone Slows LH Pulse Frequency
|
Phase 1 | |
Recruiting |
NCT02024984 -
Luteal Phase Versus Follicular Phase Administration of Clomiphene Citrate in PCOS, A Randomized Controlled Trial
|
Phase 1 | |
Completed |
NCT01709942 -
Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)
|
Phase 3 |